PARP1 and small cell lung carcinoma: We previously demonstrated the potential of proteomic profiling to identify novel therapeutic targets in SCLC such as the DNA repair proteins PARP1 and CHK1 based on differences in target expression and pathway activation between SCLC and NSCLC [3, 4].